CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or ...
MedPage Today on MSN
Major complete response rate in very high-risk bladder cancer with combo treatment
Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results